


AI FOR SCIENCE · ON THE RECORD
Biomatter
Founded by researchers who met at Vilnius University's Institute of Biotechnology; designs enzymes for a customer's target reaction with generative and physics-based models, tests each design in the lab before it ships, and sells them as custom programmes to drugmakers, reagent suppliers and food, agriculture and industrial biotech companies.
Full funding record →On the timeline →People filter →
Timeline
People
Only people the AI4S.fyi record has named: in a round, a timeline entry, commentary, an interview or a sourced role. Not the full team.
Named on AI4S.fyi
Funding rounds tracked
- 2026-11-12Series A · $18MconfirmedLed by Astanor · Existing investors UVC Partners, Inventure, MetaplanetStated use: a 2,000 m² design-and-testing facility in Vilnius opening in 2027, a larger commercial team and US presence, and continued work on the computational platform and its enzyme dataset
- 2024-08-05Seed · €6.5MconfirmedLed by Inventure, UVC Partners · Existing investors Practica Capital, MetaplanetStated use: expand the platform's capabilities and design de novo enzymes
Each round links to its line on the funding record, with its source.
Also in Protein design on the funding board
The other companies the funding board files under the same field, latest round first. A list of what the record tracks, not a ranking or a market map.
- 2026-11-09Tushen ZhihePre-A and Pre-A+ · several hundred million yuan across two roundsDesigns and optimises proteins, antibodies and cyclic peptides with its own and adapted open models on the ToursynClaw platform, tests them in automated wet labs, and is taking its own programmes toward IND filings.
- 2026-10-28BioGeometrySeries A+ · not disclosed; the A series to date tops $100MBuilds generative models for biology: GeoFlow, an all-atom model that predicts the structures of proteins and their complexes and designs binders, and GeoCell, a virtual-cell model of how cells' gene expression responds to genetic and drug perturbations. An automated lab expresses and tests the designs and feeds the data back. It designs antibodies, vaccines, peptides and enzymes for partners and its own pipeline, including synthetic-biology products.
- 2026-09-24BigHat BiosciencesSeries C · $75MDesigns antibodies with machine learning tied to a fast automated wet lab (Milliner) that makes and tests designs; its lead drug BHB810 is in the clinic.
- 2026-08-11Aureka BiotechnologiesSeries B · $100MDesigns antibodies with its own biological foundation model, AuraIDE (released in open form as OpenDDE), trained and retrained on data from its own single-cell functional screens.
- 2026-07-14Chai DiscoverySeries C · $400MBuilds AI models that predict how molecules bind and design antibodies from scratch, and licenses them to drugmakers as software.
- 2026-06-17MoleculeMindSeries A (extension) · A-series cumulative total over US$100 millionAI protein structure prediction and design (MoleculeOS, MMFold, MMDesign) sold to drugmakers and industrial-enzyme users, with a few in-house early programs.
This page compiles what AI4S.fyi has recorded and links each item to its source. It is not a grade of the organization and not its complete history: a blank means the record has not caught up as often as it means nothing happened.